Evidence map›Paper›PMID 42819403›Full record

ArticleFrontiers in cardiovascular medicine2026

Lipoprotein(a) levels and estimated QRISK3 cardiovascular risk in the Randox Health 2025 cohort: a cross-sectional analysis of 14,848 individuals.

Joanne Watt, Mary Jo Kurth, Cormac Rice, Jack Green, John V Lamont, Laura Mooney, Le Roy Dowey, Peter Fitzgerald, Mark W Ruddock

Abstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Joanne WattRandox Laboratories Ltd., Clinical Studies Group, Crumlin, United Kingdom.
Mary Jo KurthRandox Laboratories Ltd., Clinical Studies Group, Crumlin, United Kingdom.
Cormac RiceRandox Laboratories Ltd., Clinical Studies Group, Crumlin, United Kingdom.
Jack GreenRandox Laboratories Ltd., Clinical Studies Group, Crumlin, United Kingdom.
John V LamontRandox Laboratories Ltd., Clinical Studies Group, Crumlin, United Kingdom.
Laura MooneyRandox Laboratories Ltd., Clinical Studies Group, Crumlin, United Kingdom.
Le Roy DoweySchool of Biomedical Sciences, Ulster University, Coleraine Campus, Coleraine, United Kingdom.
Peter FitzgeraldRandox Laboratories Ltd., Clinical Studies Group, Crumlin, United Kingdom.
Mark W RuddockRandox Laboratories Ltd., Clinical Studies Group, Crumlin, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Lipoprotein(a) (Lp(a)) is an independent, genetically-determined cardiovascular risk factor not currently incorporated into standard cardiovascular risk prediction models such as QRISK3. Understanding the relationship between Lp(a) and estimated cardiovascular risk may identify individuals whose risk is not identified by conventional risk calculators. Methods: Analysis was performed on Results and Discussion: Among

Indexed as

cardiovascular risk predictiondyslipidaemialipoprotein(a)population screeningprimary preventionQRISK3

Identifiers

PMID42819403
PMCPMC13624064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.